Validation of the app23 transgenic mouse model of Alzheimer's disease through evaluation of risperidone treatment on aggressive behaviour

Arzneimittel-Forschung/Drug Research

Volumn 58, Issue 6, 2008, Pages 265-268

  Vloeberghs, Ellen ^a   Coen, Katrien ^a   Van Dam, Debby ^a   De Deyn, Peter Paul ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b MIDDELHEIM HOSPITAL   (Belgium)

Author keywords

Aggression lowering ability; Aggressive behaviour; Alzheimer's disease; Antipsychotic agents; CAS 106266 06 2; Risperidone; Transgenic mouse model; Validation

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; RISPERIDONE;

AGGRESSION; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; MALE; MEMORY DISORDER; MOUSE; MOUSE STRAIN; NONHUMAN; PREDICTIVE VALIDITY; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; TRANSGENIC MOUSE; VALIDATION PROCESS;

EID: 46949093968     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296505     Document Type: Article

References (25)

1. Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology. 1996;46:130-135.
2. Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiat. 1987;48:9-15.
3. Ballard CG, O'Brien J, James I, Swann A. Aggression. In: Ballard CG, O'Brien J, James I, Swann A, editors. Dementia: management of behavioural and psychological symptoms. Oxford: Oxford University Press; 2001. p. 61-78.
4. De Deyn PP. Belasting voor de patiënt en zijn omgeving. In: De Deyn PP, editor. Dementie: medische, psychosociale, ethische en preventieve aspecten. Mechelen: Kluwer; 2004. p. 105-117.
5. Ryden MB. Aggressive behavior in persons with dementia who live in the community. Alz Dis Assoc Dis. 1988;2:342-355.
6. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer's disease. IV: Disorders of behaviour. Brit J Psychiat. 1990;157:86-94.
7. De Deyn PP, Katz IR. Control of aggression and agitation in patients with dementia: efficacy and safety of risperidone. Int J Geriatr Psych. 2000;15:14-22.
8. De Deyn PP, Wirshing WC. Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioural and psychological symptoms of dementia. J Clin Psychiat. 2001;62:19-22.
9. Rabinowitz J, Katz IR, De Deyn PP, Brodaty H, Greenspan A, Davidson M. Behavioural and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone. J Clin Psychiat. 2004;65:1329-1334.
10. De Deyn PP, Katz IR, Brodaty H, Lyons B, Greenspan A, Burns A. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone. Clin Neurol Neurosur. 2005;107:497-508.
11. De Deyn PP, Buitelaar J. Risperidone in the management of agitation and aggression associated with psychiatric disorders. Eur Psychiat. 2006;21:21-28.
12. Rabinowitz J, Katz I, De Deyn PP, Greenspan A, Brodaty H. Treating behavioral and psychological symptoms in patients with psychosis of Alzheimer's disease using risperidone. Int Psychogeriatr. 2007;19:227-240.
13. Alexopoulos GS, Jeste DV, Chung H, Carpenter D, Ross R, Docherty JE The expert consensus guideline series. Treatment of dementia and its behavioural disturbances. Introduction: methods, commentary, and summary. Postgrad Med. 2005;Jan Spec No:6-22.
14. Burns A, De Deyn PP. Risperidone for the treatment of neu-ropsychiatric features in dementia. Drug Aging. 2006;23:887-896.
15. Van Dam D, D'Hooge R, Staufenbiel M, Van Ginneken C, Van Meir F, De Deyn PP. Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur J Neurosci. 2003;17:388-396.
16. Van Dam D, Vloeberghs E, Abramowski D, Staufenbiel M, De Deyn PR APP23 mice as a model of Alzheimer's Disease. An example of a transgenic breeding approach to modelling a CNS disorder. CNS Spectr. 2005;10:207-222.
17. Vloeberghs E, Van Dam D, Engelborghs S, Nagels G, Staufenbiel M, De Deyn PP. Altered circadian locomotor activity in APP23 mice: A model for BPSD disturbances. Eur J Neurosci. 2004;20:2757-2766.
18. Vloeberghs E, Van Dam D, Coen K, Staufenbiel M, De Deyn PP. Aggressive male APP23 mice modelling behavioural alterations in dementia. Behav Neurosci. 2006;120:1380-1383.
19. Meltzer HY, Lee MA, Ranjan R. Recent advances in the pharmacotherapy of schizophrenia. Acta Psychiat Scand. 1994;90:95-101.
20. Alexopoulos GS, Streim J, Carpenter D, Docherty JP; Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients. Using antipsychotic agents in older patients. J Clin Psychiatry. 2004;65 Suppl 2:5-99; discussion 100-102.
21. Moechars D, Gilis M, Kuipéri C, Laenen I, Van Leuven F. Aggressive behaviour in transgenic mice expressing APP is alleviated by serotonergic drugs. Neuroreport. 1998;9:3561-3564.
22. Van Dam D, De Deyn PP. Drug discovery in dementia: The role of rodent models. Nat Rev Drug Discov. 2006;5: 956-970.
23. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA. 1997;94:13287-13292.
24. Vloeberghs E, Van Dam D, D'Hooge R, Staufenbiel M, De Deyn PP. APP23 mice display working memory impairment in the plus-shaped water maze. Neurosci Lett. 2006;407: 6-10.
25. Van Dam D, Abramowski D, Staufenbiel M, De Deyn PR Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. Psychopharmacology (Berl). 2005;180:177-190.